Abstract
MET amplification (METamp) is a mechanism of acquired resistance to EGFR-TKIs. In INSIGHT (NCT01982955; data cut-off: September 3, 2021), the combination of tepotinib (a potent, highly selective MET-TKI) and the EGFR-TKI gefitinib (n=12) improved outcomes compared with chemotherapy (n=7) in patients with EGFR-mutant METamp NSCLC and EGFR-TKI resistance (progression-free survival hazard ratio [HR]=0.13, 90% confidence interval [CI]: 0.04, 0.43; overall survival HR=0.10, 90% CI: 0.02, 0.36). Tepotinib combined with an EGFR-TKI may therefore overcome MET-related EGFR-TKI resistance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
